Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development - Opportunities and challenges

Journal of Clinical Pharmacology

Volumn 55, Issue S3, 2015, Pages S75-S84

  Zheng, Songmao ^a   McIntosh, Thomas ^a   Wang, Weirong ^a  

^a Janssen R and D US   (United States)

Author keywords

biotherapeutics; free and total target measurements; modeling; soluble target; target engagement

Indexed keywords

BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; INTERLEUKIN 6; OMALIZUMAB; PHARMACOLOGICAL BIOMARKER; SILTUXIMAB; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ARTICLE; BINDING AFFINITY; BIOEQUIVALENCE; BIOLOGICAL THERAPY; DISSOCIATION; DISSOCIATION CONSTANT; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; ELIMINATION RATE CONSTANT; HUMAN; IMMUNOASSAY; MATHEMATICAL MODEL; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); ANIMAL; BIOLOGICAL MODEL; BLOOD; METABOLISM; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; HUMANS; MODELS, BIOLOGICAL; TREATMENT OUTCOME;

EID: 84923384658     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.357     Document Type: Article

References (56)

1. Wagner JA,. Strategic approach to fit-for-purpose biomarkers in drug development. Annu Rev Pharmacol Toxicol. 2008; 48: 631-651.
2. Kuhlmann J, Wensing G,. The applications of biomarkers in early clinical drug development to improve decision-making processes. Curr Clin Pharmacol. 2006; 1 (2): 185-191.
3. Tan DS, Thomas GV, Garrett MD, et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J. 2009; 15 (5): 406-420.
4. Chan AC, Carter PJ,. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010; 10 (5): 301-316.
5. Scott AM, Wolchok JD, Old LJ,. Antibody therapy of cancer. Nat Rev Cancer. 2012; 12 (4): 278-287.
6. Davda JP, Hansen RJ,. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. mAbs. 2010; 2 (5): 576-588.
7. Tang CY, Prueksaritanont T,. Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of 'free' and total drug and target. Pharm Res. 2011; 28 (10): 2447-2457.
8. Lee JW, Kelley M, King LE, et al. Bioanalytical approaches to quantify "total" and free therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 2011; 13 (1): 99-110.
9. Chames P, Van Regenmortel M, Weiss E, Baty D,. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009; 157 (2): 220-233.
10. Wang W, Wang EQ, Balthasar JP,. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008; 84 (5): 548-558.
11. Wang W, Wang X, Doddareddy R, et al. Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys. AAPS J. 2014; 16 (1): 129-139.
12. Meno-Tetang GM, Lowe PJ,. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Toxicol. 2005; 96 (3): 182-192.
13. Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1beta monoclonal antibody. Clin Pharmacokinet. 2012; 51 (6): e1-e18.
14. Marathe A, Peterson MC, Mager DE,. Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther. 2008; 326 (2): 555-562.
15. Vugmeyster Y, Tian X, Szklut P, Kasaian M,. Xu X. Pharmacokinetic and pharmacodynamic modeling of a humanized anti-IL-13 antibody in naive and Ascaris-challenged cynomolgus monkeys. Pharm Res. 2009; 26 (2): 306-315.
16. Betts AM, Clark TH, Yang J, et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther. 2010; 333 (1): 2-13.
17. Fetterly GJ, Aras U, Meholick PD, et al. Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J Clin Pharmacol. 2013; 53 (10): 1020-1027.
18. Haringman JJ, Gerlag DM, Smeets TJ, et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54 (8): 2387-2392.
19. Hansen RJ, Brown RM, Lu J, Wroblewski VJ,. Qualification of a free ligand assay in the presence of anti-ligand antibody Fab fragments. mAbs. 2013; 5 (2): 288-296.
20. Salimi-Moosavi H, Lee J, Desilva B, Doellgast G,. Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand. J Pharm Biomed Anal. 2010; 51 (5): 1128-1133.
21. Sloan JH, Ackermann BL, Carpenter JW, et al. A novel, high-sensitivity and drug-tolerant sandwich immunoassay for the quantitative measurement of circulating proteins. Bioanalysis. 2012; 4 (3): 241-248.
22. Neubert H, Muirhead D, Kabir M, Grace C, Cleton A, Arends R,. Sequential protein and peptide immunoaffinity capture for mass spectrometry-based quantification of total human beta-nerve growth factor. Anal Chem. 2013; 85 (3): 1719-1726.
23. Thai HT, Veyrat-Follet C, Vivier N, et al. A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects. Br J Clin Pharmacol. 2011; 72 (3): 402-414.
24. Deng R, Jin F, Prabhu S, Iyer S,. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development. Expert Opin Drug Metab Toxicol. 2012; 8 (2): 141-160.
25. Hu L, Hansen RJ, Issues,. Challenges, and opportunities in model-based drug development for monoclonal antibodies. J Pharm Sci. 2013.
26. Zhao L, Shang EY, Sahajwalla CG,. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development. J Pharm Sci. 2012; 101 (12): 4367-4382.
27. Mager DE, Jusko WJ,. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001; 28 (6): 507-532.
28. Mager DE, Krzyzanski W,. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005; 22 (10): 1589-1596.
29. Gibiansky L, Gibiansky E,. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol. 2009; 5 (7): 803-812.
30. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ,. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2007; 63 (5): 548-561.
31. Putnam WS, Li J, Haggstrom J, et al. Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS J. 2008; 10 (2): 425-430.
32. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C,. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005; 115 (3): 459-465.
33. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001; 108 (2): 184-190.
34. Racine-Poon A, Botta L, Chang TW, et al. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin Pharmacol Ther. 1997; 62 (6): 675-690.
35. Lowe PJ, Tannenbaum S, Wu K, Lloyd P, Sims J,. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol. 2010; 106 (3): 195-209.
36. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P,. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol. 2009; 68 (1): 61-76.
37. Taga T, Kishimoto T,. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 1997; 15: 797-819.
38. Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med. 2009; 206 (5): 1029-1036.
39. Ait-Oudhia S, Lowe PJ, Mager DE,. Bridging clinical outcomes of canakinumab treatment in patients with rheumatoid arthritis with a population model of IL-1beta kinetics. CPT: Pharm Syst Pharmacol. 2012; 1: e5.
40. Lindbom L, Pihlgren P, Jonsson EN,. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005; 79 (3): 241-257.
41. Sheiner LB, Beal SL,. A note on confidence intervals with extended least squares parameter estimates. J Pharmacokinet Biopharm. 1987; 15 (1): 93-98.
42. Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B,. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood. 1995; 86 (8): 3123-3131.
43. Elias N, Patterson BW, Schonfeld G,. In vivo metabolism of ApoB, ApoA-I, and VLDL triglycerides in a form of hypobetalipoproteinemia not linked to the ApoB gene. Arterioscler Thromb Vasc Biol. 2000; 20 (5): 1309-1315.
44. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM,. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006; 12 (7): 856-861.
45. Brodfuehrer J, Rankin A, Edmonds J, et al. Quantitative analysis of target coverage and germinal center response by a CXCL13 neutralizing antibody in a T-dependent mouse immunization model. Pharm Res. 2014; 31 (3): 635-648.
46. Bee C, Abdiche YN, Pons J, Rajpal A,. Determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum. PLoS ONE. 2013; 8 (11): e80501.
47. Arrowsmith J,. Trial watch: phase II failures: 2008-2010. Nat Rev Drug Discovery. 2011; 10 (5): 328-329.
48. Danhof M, de Lange EC, Della Pasqua, Ploeger OE, Voskuyl BA,. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci. 2008; 29 (4): 186-191.
49. Ploeger BA, van der Graaf PH, Danhof M,. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab Pharmacokinet. 2009; 24 (1): 3-15.
50. Agoram BM, Martin SW, van der Graaf PH,. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Discovery Today. 2007; 12 (23-24): 1018-1024.
51. Mager DE, Jusko WJ,. Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2008; 83 (6): 909-912.
52. Acosta EP, Limoli KL, Trinh L, et al. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrob Agents Chemother. 2012; 56 (11): 5938-5945.
53. Lowe PJ, Renard D,. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. Br J Clin Pharmacol. 2011; 72 (2): 306-320.
54. Allerheiligen SR,. Next-generation model-based drug discovery and development: quantitative and systems pharmacology. Clin Pharmacol Ther. 2010; 88 (1): 135-137.
55. Hainke K, Rahnenfuhrer J, Fried R,. Cumulative disease progression models for cross-sectional data: a review and comparison. Biometrical J. 2012; 54 (5): 617-640.
56. Gomeni R, Simeoni M, Zvartau-Hind M, Irizarry MC, Austin D, Gold M,. Modeling Alzheimer's disease progression using the disease system analysis approach. Alzheimer's Dementia. 2012; 8 (1): 39-50.